Orion Oyj

271560.KS · Health Technology · Pharmaceuticals: Major · FI

3,324 employees · orion.fi

About

Orion Oyj is a Finnish company that was founded in 1917 as a pharmacy in Turku. Today, Orion Oyj is a leading manufacturer of diagnostic tests, medicines, and other health products. Business model: Orion Oyj focuses on four core areas: Pharmaceutical, Diagnostics, Animal Health, and Fermion. The Pharmaceutical segment is the largest market and includes the production and sale of prescription drugs in the therapy areas of central nervous system disorders, oncology, respiratory diseases, and urology. Orion also produces generics of prescription drugs. The Diagnostics segment includes the development and production of in vitro diagnostic tests (IVDs) for clinical laboratories and point-of-care facilities. Animal Health manufactures products for animal health. Fermion produces active ingredients and intermediates for use in Orion's own and other pharmaceutical companies. Products: Orion offers a wide range of health products. The key products in the pharmaceutical segment are levodopa-based Parkinson's drugs (Stalevo, Comtess, and Opicapone) and drugs for the treatment of asthma and chronic obstructive pulmonary diseases (Easyhaler product family). ORIAHNN (Eligolix and estradiol capsules) was approved by the FDA as the first oral medication for the treatment of uterine fibroids in premenopausal women. In animal health, Orion Oyj offers products focused on the treatment of pet skin diseases, eye and ear infections, and parasite infestations. Orion also has a wide range of IVD products. The focus is on infection diagnostics, offering a wide range of medical tests to detect infections such as hepatitis B, hepatitis C, HIV, tuberculosis, human papillomavirus, and other sexually transmitted diseases. In the diagnostics segment, Orion also produces devices used in blood tests and other tests in hospitals and clinical laboratories. Future prospects: Orion Oyj is expected to invest more in the IVD segment in the coming years. The company sees significant growth potential here and plans to launch new products and test kits on the market. In addition, Orion also invests in spin-off companies focusing on the research and development of promising new technologies and therapies. Orion Oyj has been a leading player in the healthcare market for years. With a wide range of products and a strong focus on research and development, the company has built a solid foundation for future success.

Annual results

Reported figures, EUR · revenue up 22.5% in 2025

YearRevenueNet incomeNet marginFree cash flow
20251.9B500M26.5%—
20241.5B329M21.3%—
20231.2B216M18.2%—
20221.3B349M26.0%—
20211.0B193M18.5%—

Dividends per share

2026 1.80 EUR2025 1.64 EUR2024 1.62 EUR2023 1.60 EUR2022 1.50 EUR

271560.KS in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Orion Oyj are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Orion Oyj (271560.KS) — company profile and financials · MarketPulse